{"id":"W4408567665","doi":"10.1053/j.gastro.2025.02.033","title":"Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study","year":2025,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Genentech; Mitsubishi Tanabe Pharma Corporation; Celltrion; Kissei; Mylan; Boston Scientific Corporation; Teva Pharmaceutical Industries; EA Pharma Co., Ltd.; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Kyorin Pharmaceutical; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Johnson and Johnson; Takeda Pharmaceutical Company","keywords":"Crohn's disease; Medicine; Disease; Phase (matter); Internal medicine; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003246166,0.0005981948,0.001473659,0.0002185415,0.0003290513,0.0005153359,0.0005035352,0.00093842,0.001821745],"category_scores_gemma":[0.001452697,0.0002556939,0.001245285,0.0002565293,0.0006021151,0.00049683,0.0003758316,0.001541607,0.0003451537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003996384,"about_ca_system_score_gemma":0.000719714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003504256,"about_ca_topic_score_gemma":0.0009658636,"domain_scores_codex":[0.9992228,0.0004321485,0.00005948234,0.00007865354,0.0001264094,0.00008062295],"domain_scores_gemma":[0.9986236,0.0002937402,0.0004940912,0.00009446683,0.000117665,0.0003765891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7661055,0.0153391,0.02420888,0.001563891,0.002292111,0.0001596092,0.0005477289,0.0005131874,0.05408785,0.0001234379,0.002067069,0.1329916],"study_design_scores_gemma":[0.3512977,0.5085689,0.1287954,0.0001231404,0.002169745,0.0004446268,0.0001579788,0.0005481099,0.004921057,0.0001585778,0.002763605,0.00005108905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949455,0.003207939,0.0002236335,0.0002042508,0.00002919972,0.0004300326,0.000365663,0.00003762338,0.0005562696],"genre_scores_gemma":[0.9958788,0.001142552,0.0008336104,0.0004532708,0.00007325145,0.000573463,0.000693502,0.00001125086,0.0003403487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003246166,"threshold_uncertainty_score":0.01716751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122814000109858,"score_gpt":0.2668164710377605,"score_spread":0.255588331036662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}